# Newbury Pharmaceuticals > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/newburypharmaceuticals). ## Overview Newbury Pharmaceuticals is a Swedish pharmaceutical company focused on in-licensed prescription drugs, specialty medicines, and own-brand products. The company works through partnerships to register, commercialize, and distribute pharmaceuticals across the Nordic markets, while also serving selected international customers through indirect channels. ## Products & services • In-licensed prescription drugs • Specialty drugs • Own-brand pharmaceuticals • Registration and commercialization services • Nordic distribution for partner products - **In-licensed prescription drugs** (45%) — Prescription medicines acquired through licensing agreements and commercialized in Newbury's markets. - **Specialty drugs** (25%) — Specialty pharmaceutical products targeted at specific therapeutic or market niches. - **Own brands** (15%) — Products marketed under Newbury's own brand names, built around licensed product rights. - **Distribution and commercialization services** (15%) — Commercial and distribution activities for partners not directly represented in the Nordics. - In-licensed prescription drugs - Specialty drugs - Own-brand pharmaceuticals - Registration and commercialization services - Nordic distribution for partner products ## Customers Newbury sells to pharmaceutical buyers in the Nordic region and to international customers reached through indirect sales arrangements. Its customer base also includes partners that license product rights to Newbury and rely on the company for registration, market access, and commercialization. The business is built around serving patients through pharmacies, healthcare channels, and other pharmaceutical stakeholders via partner products. - **Nordic pharmacies and healthcare channels** (primary) — Buy prescription and specialty medicines for patient use in the Nordic market. - **Pharmaceutical partners** (primary) — License product rights to Newbury and use it to register and commercialize products in Scandinavia. - **International distributors and customers** (secondary) — Purchase through indirect channels outside the Nordics where Newbury extends partner products. - **Patients and end-market stakeholders** (secondary) — Indirect beneficiaries of specialty drugs and own-brand medicines commercialized by Newbury. - Nordic healthcare and pharmacy channels buying prescription medicines - International customers reached through indirect sales orders - Pharma partners seeking Nordic registration and commercialization - Buyers of specialty drugs and own-brand products - Stakeholders needing market access in Scandinavian countries ## Geography Newbury is anchored in the Nordic markets, where it focuses on building direct business and market expertise. Outside the Nordics, it pursues international sales through an indirect model, which broadens reach without requiring the same local operating footprint. The company has also noted exposure to the Middle East, where geopolitical disruption has affected freight, logistics, and the pace of business activity. - Nordic markets are the core commercial focus - Scandinavia is central to registration and commercialization work - International sales are handled through indirect channels outside the Nordics - Middle East activity is exposed to freight and logistics disruption - Geographic reach matters because market access is country-specific in pharma ## Strategy Newbury's strategy is to build a portfolio of licensed pharmaceutical products through partnerships rather than internal drug development. It aims to deepen its Nordic commercial platform, use local market knowledge to register and launch products efficiently, and extend selected products into additional markets through indirect distribution. - **Grow the licensed product portfolio** (medium-term) — A broader portfolio increases commercial reach without requiring internal R&D. - **Deepen Nordic market presence** (short-term) — Local registration and commercialization expertise is the core competitive advantage. - **Extend reach beyond the Nordics** (medium-term) — International channels diversify the customer base and broaden product monetization. - Expand the in-licensed product portfolio through partnerships - Focus on registration and commercialization rather than drug development - Strengthen direct Nordic sales and market access - Use indirect channels to reach international customers - Leverage supplier and partner networks for speed and scalability ## Risks Newbury's business depends on third-party product rights, partner relationships, and access to regulated pharmaceutical markets, so supply, licensing, and market-access execution are central risks. The company also faces external exposure to trade policy changes, tariffs, and geopolitical disruption, which can raise logistics costs and slow international activity. As in the broader pharma distribution model, regulatory compliance, product concentration, and customer payment timing can materially affect results. - **Dependence on third-party product rights** [high] — The company does not develop its own drugs and must secure licensed products from partners. - **Regulatory and registration risk** [high] — Pharmaceutical commercialization depends on approvals, registrations, and local compliance. - **Geopolitical and logistics disruption in the Middle East** [medium] — The company disclosed slower business activity and higher freight/logistics costs in the region. - **Trade policy and tariff changes** [medium] — Cross-border pharmaceutical distribution can be affected by new barriers or duties. - **Customer credit and collection risk** [high] — The company disclosed delayed payments from international sales customers. - Dependence on licensed products and partner agreements - Regulatory and market-access risk in each country - Trade policy or tariff changes could affect cross-border flows - Middle East disruption has raised freight and logistics costs - Customer payment delays can strain working capital ## Accounting Newbury's reporting is sensitive to revenue timing, receivables collectability, and valuation of partner-related balances because the business relies on commercial launches and distribution rather than long production cycles. The company also uses Swedish K3 accounting, and its reports show related-party transactions, shareholder contributions, and write-downs of subsidiary shares that can affect the parent company's results and balance sheet. Employee stock options, intercompany support, and any impairment or credit-loss judgments are important for understanding reported earnings and equity. - **Revenue recognition on pharmaceutical sales and distribution** — Affects quarterly revenue comparability - **Trade receivables and expected credit losses** — Can affect reported assets and earnings - **Related-party and partner receivables** — May influence asset carrying values - **Investment in subsidiary shares and impairment** — Can materially affect parent-company equity and profit - **Employee stock option accounting** — Affects operating costs and share count - Revenue timing may vary with product launches and distributor orders - Receivables from international customers can require collection judgments - Partner receivables tied to canceled pipeline products may need assessment - Shareholder contributions and write-downs affect parent-company equity - Employee stock option costs affect operating expenses and dilution --- *Last updated: 2026-08-11T04:04:54.794252+00:00*